Baxter International (BAX) Scheduled to Post Earnings on Friday

Baxter International (NYSE:BAX) is set to post its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Baxter International to post earnings of $0.78 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.75 billion. During the same quarter last year, the company earned $0.55 EPS. The company’s quarterly revenue was up 2.8% on a year-over-year basis. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Price Performance

Shares of BAX stock opened at $35.70 on Friday. The stock has a 50 day moving average of $37.64 and a two-hundred day moving average of $36.29. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35. Baxter International has a 12 month low of $32.06 and a 12 month high of $44.01. The company has a market capitalization of $18.21 billion, a P/E ratio of 7.35, a P/E/G ratio of 1.28 and a beta of 0.59.

Analyst Ratings Changes

Several research firms recently commented on BAX. The Goldman Sachs Group raised their target price on Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Wells Fargo & Company cut their target price on Baxter International from $44.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 7th. Citigroup raised their target price on Baxter International from $38.00 to $40.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Morgan Stanley downgraded Baxter International from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. Finally, JPMorgan Chase & Co. cut their target price on Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $41.20.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.